Other News To Note
• Discovery Laboratories Inc., of Warrington, Pa., began four research projects with its KL4 sufractant technology for acute lung injury. The preclinical studies will be in collaboration with research institutions, and funded through U.S. government-sponsored biodefense initiatives.
To continue reading subscribe now to BioWorld Today
Learn More about BioWorld Today
Already a subscriber? Sign In or Buy now to activate your subscription
Our address has changed:
BioWorld | 115 Perimeter Center Place
Suite: 1100 | Atlanta, Georgia 30346, USA
Suite: 1100 | Atlanta, Georgia 30346, USA
For Sales Inquiries:
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-770-810-3144
Fax: 1-770-810-3145
BioWorld.salessupport@thomsonreuters.com
Part of Thomson Reuters
Note: our contact information has changed
Customer Service:
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
In the U.S. and Canada: 1-800-336-4474
Outside the U.S.: 1-215-386-0100
BioWorld.support@thomsonreuters.com
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2014 Thomson Reuters. Reproduction, reposting content is strictly prohibited.
Free Ezine
Sign up for Highlights FREE e-mail newsletter